GH Research PLC (NASDAQ:GHRS) Sees Significant Growth in Short Interest

GH Research PLC (NASDAQ:GHRS) was the target of a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 2,870,000 shares, an increase of 21.1% from the January 31st total of 2,370,000 shares. Based on an average daily volume of 404,900 shares, the short-interest ratio is presently 7.1 days. Currently, 7.9% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Stifel Nicolaus increased their price objective on shares of GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Cantor Fitzgerald began coverage on shares of GH Research in a research note on Thursday, February 13th. They issued an “overweight” rating and a $14.00 price objective for the company. Royal Bank of Canada assumed coverage on shares of GH Research in a research note on Friday. They set an “outperform” rating and a $31.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of GH Research in a report on Monday, January 27th. Finally, Canaccord Genuity Group cut their price target on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $30.67.

GH Research Stock Down 0.5 %

Shares of NASDAQ GHRS opened at $10.50 on Friday. GH Research has a twelve month low of $6.00 and a twelve month high of $20.50. The firm has a fifty day simple moving average of $10.73 and a 200 day simple moving average of $9.20. The company has a market capitalization of $546.29 million, a PE ratio of -13.29 and a beta of 0.94.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.06. As a group, equities analysts expect that GH Research will post -0.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GH Research

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. RA Capital Management L.P. increased its stake in GH Research by 1.3% in the third quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock valued at $44,734,000 after purchasing an additional 85,000 shares in the last quarter. Lynx1 Capital Management LP increased its stake in GH Research by 15.8% in the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock valued at $34,013,000 after purchasing an additional 663,100 shares in the last quarter. Diadema Partners LP bought a new stake in GH Research in the fourth quarter valued at $711,000. Woodline Partners LP increased its stake in GH Research by 112.0% in the fourth quarter. Woodline Partners LP now owns 78,949 shares of the company’s stock valued at $553,000 after purchasing an additional 41,711 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in GH Research by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock valued at $508,000 after purchasing an additional 3,092 shares in the last quarter. 56.90% of the stock is owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).